ArticleNeural regeneration research2026

Targeting gangliosides to treat Alzheimer's and Parkinson's diseases: A disruptive approach with the first-in-class peptide AmyP53.

Jacques Fantini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.